Clinical trials: Phase I
Multiple Myeloma
Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma
To evaluate the safety and efficacy of Human BCMA Targeted T Cells Injection for the treatment of BCMA-positive relapsed/refractory multiple myeloma.
- Trial name
- NCT04003168
- Testing
- Human BCMA targeted T Cells Injection
- Where
- 3 sites in China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Kidney Disease
A Study of GSK4771261 in Healthy Participants Aged 25 to 55 Years of Age Inclusive
This is a first time in Asia (FTIA) study of GSK4771261 in healthy participants of Chinese, Japanese, and White/European ancestry.
- Trial name
- NCT07600450
- Testing
- GSK4771261
- Where
- Netherlands
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Malignant Melanoma, Neoplasms
A Study on the Effect of Vemurafenib on the Pharmacokinetics of a Single Dose of Tizanidine in Patients With BRAFV600 Mutation-Positive Metastatic Malignancies
This open-label, multicenter, 3-period, fixed-sequence study will evaluate the effect of multiple oral doses of vemurafenib on the pharmacokinetics of a single oral dose of tizanidine in participants with BRAFV600…
- Trial name
- NCT01844674
- Testing
- Tizanidine, Vemurafenib
- Where
- 12 sites in United States, Brazil and 3 more
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Abdominal Aortic Aneurysm
A Phase I Evaluation of the Safety of the TriVascular Stent-Graft System in the Treatment of Abdominal Aortic Aneurysms
This study was a prospective observational study examined the safety of the TriVascular AAA Stent-Graft System in the elective treatment of patients with abdominal aortic aneurysms.
- Trial name
- AAA IDE (NCT00646048)
- Testing
- TriVascular Stent-Graft System
- Where
- 7 sites in United States
- Volunteers
- 43 people
- Sponsor
- Boston Scientific Corporation
Brain Cancer, Central Nervous System Diseases
DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas
The goal of this clinical research study is to find the highest tolerable dose of DNX-2401 that can be injected directly into brain tumors and into the surrounding brain tissue where tumor cells can multiply.
- Trial name
- NCT00805376
- Testing
- DNX-2401, Tumor Removal
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- DNAtrix, Inc.
Phase 1 Study, Healthy Volunteers
Evaluate the Pharmacokinetics and Safety of DWP14012 Tablet A and Compare Those of DWP14012 Tablet B in Healthy Subjects
The pharmacokinetics (PK) and safety of oral DWP14012 tablet A will be evaluated and compared with those of DWP14012 tablet B in healthy subjects.
- Trial name
- NCT05149274
- Testing
- DWP14012 Tablet A, DWP14012 Tablet B
- Where
- South Korea
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Neoplasms
Japanese BAY1000394 Monotherapy Phase I Study
This is an open-label, non-randomized, dose-escalating Phase I study to evaluate the safety, tolerability, pharmacokinetics of BAY1000394 given in a 3 days on / 4 days off schedule in Japanese subjects with advanced malignancies.
- Trial name
- NCT02047890
- Testing
- BAY1000394 (2.5mg), BAY1000394 (5mg)
- Where
- 2 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Bayer
Neoplasms
A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours
The main objective of the dose-escalation part of the trial is to determine the safety and tolerability, and to determine the Maximum Tolerated Dose and/or the Recommended Phase 2 Dose (RP2D) of BI 754091 on the basis of patients…
- Trial name
- NCT02952248
- Testing
- BI 754091
- Where
- 13 sites in United States, Canada and 1 more
- Volunteers
- 110 people
- Sponsor
- Boehringer Ingelheim
Healthy
A Study to Examine the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of TMC435 in Healthy Chinese Participants
The purpose of this study is to determine the pharmacokinetics (what the body does to a medication) of TMC435 after multiple oral doses of 100 and 150 mg TMC435 once daily for 7 days in healthy Chinese participants.
- Trial name
- NCT02071355
- Testing
- TMC435 100 mg, TMC435 150 mg
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Hepatic Impairment
A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function
This is a Phase I open-label study to evaluate the pharmacokinetic (PK) profile of a single oral dose of vadadustat in subjects with hepatic impairment(HI) compared to healthy matched control subjects with normal hepatic function.
- Trial name
- NCT03799848
- Testing
- Vadadustat
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Akebia Therapeutics
B Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)
The purpose of this study is to test the safety and efficacy of AUTO3, a CAR T cell treatment targeting CD19 and CD22 in paediatric or young adult patients with relapsed or refractory B cell acute lymphoblastic leukaemia.
- Conditions
- B Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Refractory Childhood Acute Lymphoblastic Leukemia, B-cell Acute Lymphoblastic Leukemia
- Trial name
- AMELIA (NCT03289455)
- Testing
- AUTO3 (CD19/22 CAR T cells
- Where
- 3 sites in United Kingdom
- Volunteers
- 23 people
- Sponsor
- Autolus Limited
Lipoprotein Lipase Deficiency, Familial, Hyperlipoproteinemia Type I
Pilot Study To Assess CAT-2003 in Patients With Chylomicronemia
The purpose of this study is to assess safety and efficacy of CAT-2003 in patients with chylomicronemia. The study will evaluate the effects of CAT-2003 on fasting total and chylomicron triglyceride levels, as well as…
- Conditions
- Lipoprotein Lipase Deficiency, Familial, Hyperlipoproteinemia Type I, Chylomicronemia, Familial, Hypertriglyceridemia
- Trial name
- NCT02098278
- Testing
- CAT-2003
- Where
- 2 sites in Canada
- Volunteers
- 13 people
- Sponsor
- Catabasis Pharmaceuticals
Advanced Solid Tumor or Hematologic Tumor
A Phase I Study of TQB728 Tablets on Tolerance and Pharmacokinetics
This is a open-label, phase I study to evaluate tolerance and pharmacokinetics of TQB3728 tablets in subjects with advanced solid tumor or hematologic tumor.
- Trial name
- NCT04523285
- Testing
- TQB3728
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Neoplasm, Gastric
Study of Pemetrexed Plus Cisplatin in Advanced Gastric Cancer
This is a multicenter, single arm, open-label Phase 1/2 study of pemetrexed plus cisplatin for patients with unresectable, advanced gastric cancer who had no prior palliative chemotherapy.
- Trial name
- NCT00320515
- Testing
- pemetrexed, cisplatin
- Where
- 8 sites in Argentina, Mexico and 2 more
- Volunteers
- 89 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer
Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma
Phase I will determine the MTD and evaluated the safety profile of oral lenalidomide on days 1-21 when given with liposomal doxorubicin on day 1 of every 28 day cycle Phase II will commence once the MTD is established, additional…
- Trial name
- NCT00179725
- Testing
- CC-5013, liposomal doxorubicin
- Where
- 5 sites in United States
- Volunteers
- 60 people
- Sponsor
- Celgene Corporation
Nasopharyngeal Carcinoma
SHR-1701 in Combination With Famitinib in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
This is an open label, multi-center, phase I/II study to evaluate the efficacy and safety of SHR-1701 in combination with famitinib in subjects with recurrent/metastatic nasopharyngeal carcinoma(R/M NPC).
- Trial name
- NCT05020925
- Testing
- SHR-1701, Famitinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Healthy Volunteer Study
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Ethinyl Estradiol/Levonorgestrel (EE/LNG)
Drug-drug interaction study between Ethinyl Estradioll/Levonorgestrel and Bemnifosbuvir/Ruzasvir
- Trial name
- NCT07272889
- Testing
- Ethinyl Estradioll/Levonorgestrel (EE/LNG), Bemnifosbuvir/Ruzasvir (BEM/RZR), Bemnifosbuvir/Ruzasvir (BEM/RZR) + Ethinyl Estradioll/Levonorgestrel (EE/LNG)
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Atea Pharmaceuticals, Inc.
Healthy Participants
A Study to Assess the Pharmacokinetics, Safety and Tolerability of Single-dose Adagrasib (BMS-986503) in Healthy Participants of Japanese Descent
The aim of this study is to assess the pharmacokinetics, safety and tolerability of single-dose Adagrasib (BMS-986503) in healthy participants of Japanese descent
- Trial name
- NCT07723118
- Testing
- Adagrasib
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Mirati Therapeutics Inc.
Healthy
A Study of JNJ-64251330 in Healthy Participants
The purpose of this study is to evaluate: systemic and local gut (rectum and sigmoid colon) exposure to JNJ-64251330, local tissue Pharmacodynamics (PD) using gut (rectum and sigmoid colon) biopsies (Part 1) and the effect of…
- Trial name
- NCT04552197
- Testing
- JNJ-64251330, Tofacitinib
- Where
- Belgium
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Drug Interactions
A Drug Interaction Study of BIIB074 and an Oral Contraceptive Regimen
The primary objective of this study is to evaluate the effect of multiple doses of a uridine diphosphate glucuronosyltransferases (UGT)-inducing oral contraceptive (OC) regimen (ethinyl estradiol and levonorgestrel) on the PK of…
- Trial name
- NCT03324685
- Testing
- BIIB074, OC (ethinyl estradiol and levonorgestrel)
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Biogen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.